Close Menu

More articles about Companion Diagnostics

Through the formation of the Asian Cancer Research Group, Eli Lily, Merck, and Pfizer have also committed "to create one of the most extensive pharmacogenomic cancer databases known to date."

An AHRQ official provided updates on the agency's ongoing activities in the personalized medicine field, including the development of a BRCA testing decision-support tool; a draft report on frameworks for gauging genetic testing quality; and a randomized-controlled trial on pharmacogenomics warfarin dosing that is unlikely to change the standard of care.

The French firm will work with MD Anderson on a potential companion diagnostic for its drug candidate for treating solid tumors.

Roche filed the suit yesterday in response to DxS' efforts to terminate a molecular diagnostics distribution deal.

Qiagen this week updated investors on how its recent spate of acquisitions, licensing agreements, and partnerships will drive organic growth in its sample preparation and PCR-based molecular diagnostics business.

A Novartis spokesperson told Pharmacogenomics Reporter last week that the company "plans to have discussions with the FDA about the specific requirements for the approval of lumiracoxib when used in conjunction with a biomarker program."

Pfizer and Qiagen have expanded their personalized medicine portfolio with an Rx/Dx collaboration in glioblastoma multiforme.

The company plans to use the PI3K gene to develop companion diagnostics for cancer drugs.

Qiagen's DxS subsidiary will develop a PCR-based test to help identify ideal patients for a vaccine that Pfizer is developing for glioblastoma multiforme.

A Novartis official suggested that the resubmission of lumiracoxib could be the "first example" of a molecular diagnostic-based "drug rescue" in the industry.

"Our data reinforce the importance of the KRAS mutation as a predictive biomarker for responsiveness to Vectibix therapy," said Roger Perlmutter, Amgen's executive vice president of research and development.

If the researchers are successful, GMU's Emanuel Petricoin believes it could lead to the development of the first ever protein activation companion assay.

AstraZeneca said the alliance with Dako is the first in a series of alliances planned with diagnostic companies in personalized medicine.

In the latter part of December, Clinical Data’s PGxHealth division inked a research collaboration with the German Heart Institute to “conduct one of the largest retrospective case/control studies to date to validate genetic variants associated with response” to Plavix. With this study, the partners hope to further inform the clinical utility of a pharmacogenetic test in determining best-responders to the anti-platelet agent.

The most widely read articles in Pharmacogenomics Reporter in 2009 included stories on the American Civil Liberties Union's lawsuit against Myriad Genetics and other patent holders of BRCA mutations; the US Food and Drug Administration's labeling updates to the anti-platelet agent Plavix, as well as the colorectal cancer drugs Erbitux and Vectibix; the growth of direct-to-consumer genomics services, such as 23andMe and Navigenics; Myriad's position on genetic counseling; and big pharma's reasons for investing in personalized medicine.

Affomix will use its Y2HExpress technology to select antibodies for Kalgene with potential diagnostic and therapeutic use in breast cancer.

Clarient plans to commercialize Applied Genomics' five-antibody immunohistochemistry test for non-small cell lung cancer, called Pulmotype, within its network of pathologists by the first quarter of 2010.

The partners will evaluate and identify markers associated with response to the antiplatelet agent clopidogrel (Plavix).

Genomic Health has been conducting a number of studies to examine how well its RT-PCR-based Oncotype DX test compares to IHC and FISH for assessing the HER2 status of breast cancer patients.

RBM's Psynova Neurotech subsidiary will collaborate with Roche on developing companion diagnostics for schizophrenia treatments.


The Hastings Center's Erik Parens argues in a Scientific American opinion piece that the current pandemic underscores the need to reconsider the hope placed in genomic medicine. 

The Los Angeles Times writes that Operation Warp Speed has an ambitious timeline for developing a COVID-19 vaccine.

The Sydney Morning Herald reports that Australia is launching its trial of preconception carrier testing Tuesday.

In PNAS this week: autosomal genes commonly affected by loss-of-function variants, variants implicated in testis development disorders, and more.